Skip to main content
. 2019 Apr 9;25:2609–2622. doi: 10.12659/MSM.913471

Table 2.

Clinical and pathological information of CESC patients.

Clinical feature Variable Patients (%)
Age at diagnosis (years) >60 59 (19.4)
≤60 245 (80.6)
Race White 209 (68.8)
Black or African American 30 (9.87)
Native Hawaiian or other Pacific islander 2 (0.61)
Asian 20 (6.58)
American Indian or Alaska native 7 (2.3)
Other 36 (11.84)
Clinical stage Stage I 162 (53.29)
Stage II 69 (22.7)
Stage III 45 (14.8)
Stage IV 21 (6.91)
Other 7 (2.3)
Neoplasm histologic grade g1 18 (5.92)
g2 135 (44.41)
g3 118 (38.82)
g4 1 (0.33)
gx 24 (7.89)
Other 8 (2.63)
HPV status Indeterminate 1 (0.33)
Negative 22 (7.24)
Positive 281 (92.43)
Menopause status Pre (<6 months since lmp and no prior bilateral ovariectomy and not on estrogen replacement) 124 (40.79)
Post (prior bilateral ovariectomy or >12 mo since lmp with no prior hysterectomy) 82 (26.97)
Peri (6–12 months since last menstrual period) 25 (8.22)
Indeterminate (neither pre or postmenopausal) 3 (0.99)
Other 70 (23.03)
Lymphovascular involvement Absent 71 (23.36)
Present 79 (25.99)
Other 154 (50.65)
Pathology T stage T1 140 (46.05)
T2 71 (23.36)
T3 20 (6.58)
T4 10 (3.29)
Tis 1 (0.33)
Tx 17 (5.59)
Other 45 (14.8)
Pathology N stage N0 133 (43.75)
N1 60 (19.74)
Nx 66 (21.71)
Other 45 (14.8)
Pathology M stage M0 116 (38.16)
M1 10 (3.29)
Mx 128 (42.1)
Other 50 (16.45)